CRA_8696

CRA_8696 is an experimental small molecule compound developed by Axys Pharmaceuticals. It acts as a reversible inhibitor of trypsin-like serine proteases, specifically targeting prothrombin (Factor II), urokinase-type plasminogen activator (uPA), and serine protease 1 (trypsin-1). The compound was designed to bind within the highly homologous S1 subsite of these enzymes to explore structural determinants of potency and selectivity, offering potential utility in the treatment or prevention of thromboembolic disorders and cancer. CRA_8696 is documented in DrugBank under accession number DB03159 and remains categorized within the experimental group, as it has not progressed to clinical evaluation or regulatory approval.

Other names

3-{5-[amino(iminio)methyl]-1H-indol-2-yl}-1,1'-biphenyl-2-olate2-[5-(amino-azaniumylidene-methyl)-1H-indol-2-yl]-6-phenyl-phenolate